Abstract
Asthma is a complex disorder affected by numerous factors, both genetic and environmental. This article aims to build a profile of the patenting activity in the area of asthma drugs over the past five years and indicates the most prolific companies in terms of the numbers of patents published. Also presented are the details of those antiasthma agents which are currently under preclinical evaluation or in Phase II/III clinical trials.